Crossmark

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of OBI-858 for the Treatment of Moderate-to-Severe Glabellar Lines

Crossref DOI link: https://doi.org/10.1007/s13555-025-01561-5

Published Online: 2025-11-01

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yen, Yu-Hsiu

Tsau, Tzu-Wen

Lee, Chih-Hung

Chen, Hsin-Han

Lin, Chih-Hung

Chen, Tim-Mo

Pu, Chi-Ming
License Information

Text and Data Mining valid from 2025-11-01

Version of Record valid from 2025-11-01
More Information

Article History

Received: 29 August 2025

Accepted: 26 September 2025

First Online: 1 November 2025

Declarations

:

: Tzu-Wen Tsau is the stakeholder of OBIGEN PHARMA, INC. Yu-Hsiu Yen, Chih-Hung Lee, Hsin-Han Chen, Chih-Hung Lin, Tim-Mo Chen and Chi-Ming Pu declare no conflict of interest for this article.

: This study was reviewed and approved by the IRB of all participating institutions. Master approval was granted by the Chang Gung Memorial Hospital IRB (approval number: 202400831A0), with additional approvals obtained from Cathay General Hospital (CGH-CS113009), China Medical University Hospital (CMUH113-REC1-118), and Tri-Service General Hospital (C202401020). Written informed consent was obtained from all participants before enrolment, including consent for publication of any identifiable information. The study was conducted in accordance with the Declaration of Helsinki (1964, as revised in 2013) and local regulatory requirements.

Document is current

Any future updates will be listed below